Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

BACKGROUND: The JACOB trial (NCT01774786) was a double-blinded, placebo-controlled, randomized, multicenter, international, phase III trial evaluating the efficacy and safety of adding pertuzumab to trastuzumab and chemotherapy in first-line treatment of human epidermal growth factor receptor 2 (HER...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Commun (Lond)
Hlavní autoři: Liu, Tianshu, Qin, Yanru, Li, Jin, Xu, Ruihua, Xu, Jianming, Yang, Shujun, Qin, Shukui, Bai, Yuxian, Wu, Changping, Mao, Yixiang, Wu, Haiyan, Ge, Yilin, Shen, Lin
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6591878/
https://ncbi.nlm.nih.gov/pubmed/31234927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-019-0384-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky